Alginate-based Vaccine Development Service

Alginate-based Vaccine Development Service at CD BioGlyco

Marine carbohydrates are usually biodegradable and biocompatible and exhibit biological properties. Among them, alginate, a natural polyanionic polysaccharide, has become one of the hotspots of research due to its abundant sources, biocompatibility, flexibility of modification, and other properties or physiological functions. CD BioGlyco provides high-quality vaccine development services using alginate as an adjuvant based on the biological properties of alginate.

Preparation of Adjuvant

We use marine carbohydrate nanoparticles coated with alginate as an adjuvant for vaccines. They are mixed into colostrum at the time of production, break the larger droplets in it, and finally obtain a stable and homogeneous emulsion.

On the other hand, to obtain adjuvants with better performance, we also provide a test for their particle size and Zeta potential.

Fig.1 Preparation process of adjuvants. (CD BioGlyco)

Development of Vaccines

We prepare vaccines through a series of processes that involve adjusting the pH of marine carbohydrate solutions, autoclaving them, and mixing them with adjuvants, antigens, surfactants, and stabilizers.

Second, we offer in vitro and in vivo assays to detect vaccine effects. For example, ELISA is used to determine the seroconversion rate or the presence of antibodies in vaccinated mice. For some infectious diseases with animal models, attack experiments of pathogens can be used to evaluate the protective effect of the vaccine and optimize the immunization procedures and vaccination routes through experiments.

Fig.2 Flowchart of vaccine development. (CD BioGlyco)

Publication

Technology: Emulsification method, in vivo experiments in mice

Journal: Current Pharmaceutical Design

IF: 3.1

Published: 2017

Results: In this work, inactivated Bordetella pertussis bacterial cells encapsulated by alginate particles were prepared and evaluated for in vivo immunogenicity and efficacy of a particle-based vaccine in mice. Micro-pellet loaded with inactivated Bordetella pertussis bacterial cells using an emulsification method was produced and characterized. According to the experiments, it was found that the best conditions for the preparation of the microspheres were a surfactant of 3.6 (% w/v), a homogenization speed of 600 rpm, as well as a cross-linking time of 3 min. The average particle size of the microspheres was 151.1 μm, the index of polydispersity was 0.43, 89.6% of the loading efficiency was achieved, and 36.3% of the loading capacity, with a relatively constant release rate lasting for 15 days. It is concluded that inactive Bordetella pertussis cell micellization appears to be a suitable method to improve the wP vaccine quality, particularly by obtaining good immunogenicity with a low bacterial content.

Applications

• The development of alginate vaccines can be used to explore the response rate of the body's immune system and the duration of immune effects.
• The development of alginate vaccines can be used to expand the biological functions of marine carbohydrates.
• The development of alginate vaccines can be used for in-depth research and development of vaccines with antimicrobial activity.

Advantages

• The vaccines we develop are quality tested to ensure high quality and stability.
• According to the research needs of our clients, our R&D team provides custom vaccine development solutions.
• We have proven vaccine development technology to help clients solve any research challenges.

Depending on the research on marine organisms, CD BioGlyco offers numerous services. Examples include the Production of Marine Carbohydrates and the Modification and development of Related Adjuvants and Vaccines. We have established a comprehensive vaccine development platform to provide our clients with high-quality vaccine development services. Please feel free to contact us if you would like further information.